Concepedia

I. Sklenar

IS

15

Publications

451

Citations

13

H-Index

1977

Active since

Affiliations

Novartis (Switzerland)(Current)

University of Basel

Novartis (United States)

I. Sklenar is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and immunology.

Top concepts

Publications per year

1977–2007

15

Publications

15

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Miklos Pless, Karim Belhadj, Hans D. Menssen et al. · Clinical Cancer Research · 2004 · 52 citations

Association of Symptomatic Human Infection with Toxoplasma gondii with Imbalance of Monocytes and Antigen-Specific T Cell Subsets

I. Sklenar, Terry C. Jones, Ş. Ş. Alkan et al. · The Journal of Infectious Diseases · 1986 · 48 citations · Full text

, , +13

Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.

Salvatore Siena, Marco Bregni, L Bonsi et al. · PubMed · 1993 · 42 citations

Spontaneous Hypoglycemia Associated With Autoimmunity Specific to Human Insulin

I. Sklenar, Terence J. Wilkin, José-Luis Dı́az et al. · Diabetes Care · 1987 · 41 citations

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

Lillian L. Siu, Eric K. Rowinsky, Lisa A. Hammond et al. · PubMed · 2002 · 41 citations

Rows per page

1–5 of 15